The Center for Clinical Molecular Medical Detection, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P. R. China.
Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing 400016, P. R. China.
Theranostics. 2019 Mar 16;9(7):1993-2002. doi: 10.7150/thno.31943. eCollection 2019.
Effective characterization of protein biomarkers status on the cell surface has important value in the diagnosis and treatment of diseases. Traditional immunohistochemistry can only assess the protein expression level rather than accurately reflect their interaction and oligomerization, resulting in inevitable problems for personalized therapy. Herein, we developed a novel DNAzyme-catalyzed tyramide depositing reaction (DCTDR) for in situ amplified imaging of membrane protein status. By using human epidermal growth factor receptor 2 (HER2) as model, the binding of HER2 proteins with specific aptamers induced the formation of activated hemin/G-quadruplex (G4) DNAzyme on the cell surface to catalyze the covalent deposition of fluorescent tyramide on the membrane proteins for fluorescence imaging. The DCTDR-based imaging can conveniently characterize total HER2 expression and HER2 dimerization on the breast cancer cell surface with the application of aptamer-G4 probes and proximity aptamer-split G4 probes, respectively. The designed DCTDR strategy was successfully applied to quantitatively estimate total HER2 expression and HER2 homodimer on clinical breast cancer tissue sections with high specificity and accuracy. The DCTDR strategy provides a simple, pragmatic and enzyme-free toolbox to conveniently and sensitively analyze protein status in clinical samples for improving clinical research, cancer diagnostics and personalized treatment.
有效表征细胞表面蛋白质生物标志物状态在疾病的诊断和治疗中具有重要价值。传统的免疫组织化学只能评估蛋白质表达水平,而不能准确反映其相互作用和寡聚化,从而为个性化治疗带来了不可避免的问题。在此,我们开发了一种新型的 DNA 酶催化酪胺沉积反应(DCTDR),用于膜蛋白状态的原位放大成像。用人表皮生长因子受体 2(HER2)作为模型,HER2 蛋白与特异性适体的结合诱导激活的血红素/G-四链体(G4)DNA 酶在细胞表面形成,从而催化荧光酪胺在膜蛋白上的共价沉积,用于荧光成像。基于 DCTDR 的成像可以方便地表征乳腺癌细胞膜表面总 HER2 表达和 HER2 二聚化,分别应用适体-G4 探针和邻近适体分裂 G4 探针。所设计的 DCTDR 策略成功应用于定量估计临床乳腺癌组织切片中总 HER2 表达和 HER2 同源二聚体,具有高特异性和准确性。DCTDR 策略为方便、灵敏地分析临床样本中的蛋白质状态提供了一种简单、实用且无酶的工具包,用于改善临床研究、癌症诊断和个性化治疗。